Clinical Trials
12 trialsNCT07302347 2026-06-05
MK-3475-G21
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT03349450 2026-05-06
SPiReL
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT04268277 2026-02-27
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
University of Ulm
Phase 2 Terminated
NCT03445858 2026-02-18
Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults
Children's Hospital Medical Center, Cincinnati
Phase EARLY_PHASE1 Completed
NCT03013218 2025-08-01
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
Phase 1 Completed
NCT03884556 2025-07-02
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Trishula Therapeutics, Inc.
Phase 1 Completed
NCT02783300 2025-03-10
Meteor 1
GlaxoSmithKline
Phase 1 Completed
NCT03058289 2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2 Completed
NCT02595866 2024-08-09
Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT05296772 2023-09-06
Phase 1 First-in-human Study of JS014
Anwita Biosciences
Phase 1 Unknown
NCT02376699 2023-05-01
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
Phase 1 Terminated
NCT01986426 2018-10-03
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
Lytix Biopharma AS
Phase 1 Completed